share_log

GlaxoSmithKline | 6-K: Strong Year-to-Date and Q3 Performance Drives Upgrade to Full-Year Guidance

SEC announcement ·  Nov 1, 2023 12:51
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more